AI Article Synopsis
- Researchers immunized three-month-old Alzheimer's disease model mice with a specific vaccine via nasal inhalation and found increases in Aβ42 antibody levels in the treated groups.
- The vaccine AdCpG-(Aβ3-10)10 triggered significant splenocyte proliferation and modified cytokine levels, increasing IL-4 and IL-10 while decreasing IL-2 and interferon-γ in the AdCpG(Aβ3-10)10 group.
- Overall, the study suggests that this vaccine elicits a strong humoral immune response while minimizing T cell-mediated cytotoxicity associated with Aβ1-42.
Article Abstract
Three-month-old Alzheimer's disease model transgenic mice were immunized with Aβ1-42 Plp-Adenovirus [Ad]-X-CMV-(Aβ3-10)10-CpG [AdCpG-(Aβ3-10)10] or AdCpG virus fluid via nasal mucosal inhalation, respectively. ELISA analysis of serum showed Aβ42 antibody titers were significantly increased in mice immunized with Aβ1-42 and AdCpG-(Aβ3-10)10. Concanavalin A and AdCpG-(Aβ3-10)10 stimulation significantly increased the number of proliferating spleen cells cultured from AdCpG(Aβ3-10)10 and Aβ42 groups compared with the control group. In the AdCpG(Aβ3-10)10 group, levels of interleukin (IL)-4 and IL-10 were increased, while those of IL-2 and interferon-γ were decreased. In the Aβ42 group, levels of IL-4, IL-10, IL-2 and interferon-γ were all increased. Experimental findings indicate that AdCpG-(Aβ3-10)10 vaccine can produce strong T helper 2 (Th2) humoral immune responses in addition to the production of Aβ42 antibody. The cellular immunologic response was weak and avoided Aβ1-42-mediated cytotoxicity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4146261 | PMC |
| http://dx.doi.org/10.4103/1673-5374.131605 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!